2 completed, 2 terminated, 1 withdrawn. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 2, Terminated 2, Withdrawn 1 |
Follow reteplase: new trials by email Literature Review of reteplase trials Research Report on reteplase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE） Injection of recombinant human tissue plasminogen kinase derivatives, Recombinant human tissue plasminogen activator - Acute Ischemic Stroke | Phase 3 | Completed | Angde Biotech Pharmaceutical Co., Ltd. | 1412 | 2022-03-21 | 2024-03-04 |
| Efficacy and Safety of CUSA-081 in the Restoration of Dysfunctional Central Venous Access Device (CVAD) Functionality CUSA-081 - Restoration of Function to CVADs | Phase 3 | Withdrawn | Chiesi Farmaceutici S.p.A. | 2022-02-28 | 2022-04-15 | |
| Effect of Low-dose Intracoronary Reteplase on Myocardial Infarct Size During Primary Percutaneous Coronary Intervention Normal Saline, Reteplase Injection 9mg, Reteplase Injection 18mg - Acute ST-segment Elevation Myocardial Infarction | Phase 3 | Terminated | Ge Junbo | 36 | 2021-07-01 | 2023-09-14 |
| Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality CUSA-081, Placebo, Alteplase - Catheter Occlusion, Thrombosis | Phase 3 | Terminated | Chiesi Farmaceutici S.p.A. | 462 | 2020-02-12 | 2024-08-23 |
| A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse) abciximab placebo; reteplase placebo, abciximab, abciximab, Abciximab; reteplase; abciximab placebo; abciximab, abciximab; reteplase placebo; abciximab placebo; abciximab - Myocardial Infarction | Phase 3 | Completed | Centocor, Inc. | 2461 | 2002-08-01 | 2014-07-31 |
Bites and Stings (1) · Ischemic Stroke (1) · Myocardial Infarction (1) · ST Elevation Myocardial Infarction (1) · Thrombosis (1)
Chiesi Farmaceutici S.p.A. (2) · Angde Biotech Pharmaceutical Co., Ltd. (1) · Centocor, Inc. (1) · Ge Junbo (1)
United States (3) · Argentina (2) · Belgium (2) · Bulgaria (2) · China (2) · Czechia (2) · Poland (2) · Romania (2) · Spain (2) · Austria (1) · Canada (1) · Denmark (1) · France (1) · Germany (1) · Hungary (1)
Junbo Ge (1) · Yongjun Wang (1)
PMID 15077099, PMID 18499565, PMID 19850248, PMID 19850249, PMID 20170878, PMID 35800360, PMID 38286482, PMID 38884332, PMID 40180551, PMID 42089199
2019 (1)